http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2491291-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f8a9ae8adba13cd2b184a57f0c7a5ec |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-531 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K9-00 |
| filingDate | 2009-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2802f768538e7bc1c773ddcf821e338a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_205911686a2a8f964d88f4d4ddf6a20a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e0201457ab420da6924e758a3e31ee84 |
| publicationDate | 2013-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2491291-C2 |
| titleOfInvention | Modified peptide and using it for cns cancer screening and therapeutic effectiveness tests |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention describes a chemically modified peptide that is a fragment of human protein S100β consisting of a sequence of 15 amino acids corresponding to the amino acids in position 18-32 of the amino acid sequence of protein S100β. The peptide is covalently bound to a spacer (Ahx) consisting of 2-aminoheptane acid or a similar compound, and covalently bound to the spacer by a biotin molecule (Bio). The peptide is described by general formula: A-Tyr 1 -Ser 2 -Gly 3 -Arg 4 -Glu 5 -Gly 6 -Asp 7 -Lys 8 -His 9 -Lys 10 -Leu 11 -Lys 12 -Lys 13 -Ser 14 -Glu 15 -E, wherein A represents Bio-Ahx, Bio-Acp, Bio or 0, and B represents 0 or -NH 2 . Bio means biotin; Ahx means a residue of 2-aminoheptane acid; Acp means a residue of 6-aminocapronic acid, 0 means the absence of any amino acid. A diagnostic technique and a method for prediction of melanoma provides measuring blood natural antibodies (nAB) to the peptide according to the invention with the stages of melanoma diagnosed by the antibody concentration as compared to the reference. The clinical outcome and therapeutic effectiveness in a craniocereberal injury are predicted by measuring the nAB to the peptide according to the invention. If observing the blood nAB level in the patients lower as compared to the standard reference, the favourable clinical outcome is diagnosed, and the therapy is stated to be effective. n EFFECT: invention may be used effectively as instant diagnosing of the disturbed blood-brain barrier and monitoring of the clinical effectiveness in CCIs and some cancers. n 3 cl, 9 dwg, 1 tbl, 5 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017176385-A1 |
| priorityDate | 2009-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 34.